Drug Profile
Research programme: anti-folate receptor beta antibodies - Innovatis Pharma Corporation
Alternative Names: IP 1001ELatest Information Update: 29 Jun 2016
Price :
$50
*
At a glance
- Originator Innovatis Pharma Corporation
- Class Drug conjugates
- Mechanism of Action Folate receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Immunological disorders; Leukaemia; Rheumatoid arthritis; Septic shock
Most Recent Events
- 29 Jun 2016 Discontinued - Preclinical for Immunological disorders in Japan (unspecified route)
- 29 Jun 2016 Discontinued - Preclinical for Leukaemia in Japan (unspecified route)
- 29 Jun 2016 Discontinued - Preclinical for Rheumatoid arthritis in Japan (unspecified route)